leadf
logo-loader
viewNeuren Pharmaceuticals Ltd

Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial

Neuren Pharmaceuticals' (ASX:NEU) Jon Pilcher speaks to Proactive's Andrew Scott following the news they've received approval for the final stage of its NNZ-2591 clinical trial. The Phase 1 trial in Australia is evaluating the safety, tolerability and pharmacokinetics of the drug in healthy adult volunteers before advancing to Phase 2 trials in patients next year.

Quick facts: Neuren Pharmaceuticals Ltd

Price: 1.25 AUD

ASX:NEU
Market: ASX
Market Cap: $147.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Neuren Pharmaceuticals Ltd named herein, including the promotion by the Company of Neuren Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lithium Australia talks pilot testing of its LieNA® lithium conversion process

Lithium Australia NL's (ASX:LIT) Adrian Griffin caught up with Proactive's Andrew Scott following the news they're to pilot test its LieNA® lithium conversion process. He recaps on what sets the process apart from conventional “converters” and spells out the testing schedule ahead of a planned...

2 days, 7 hours ago

2 min read